Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742210 | 0.81 | ADORA2B (0.60) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5739936 | 0.75 | ADORA2B (0.57) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5742397 | 0.73 | ADORA2B (0.55) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5785083 | 0.73 | KDM4E (0.41) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5740691 | 0.68 | ADORA3 (0.50) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6094933 | 0.65 | — | — | |
| SCHEMBL5229724 | 0.65 | ALDH1A1 (0.52) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL6092557 | 0.64 | ADORA2A (0.45) | ALDH1A1ADORA2AADORA1ADORA2BKDM4E | |
| SCHEMBL11795918 | 0.64 | ALDH1A1 (1.00) | ALDH1A1ADORA2AADORA1ADORA2BKDM4E | |
| SCHEMBL5741805 | 0.64 | ADORA3 (0.53) | ALDH1A1ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637532-A1 | FUSED PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252780-A1 | Fused pyrimidine derivatives | INSR, GPR119, NPY4R | ALDH1A1 3942/4885ADORA2A 1417/4885ADORA1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.